ATM and non-small cell lung carcinoma: Our conclusions were then further validated using an external cohort of 2727 NSCLC patients (48 with pathogenic/likely pathogenic ATM/ATR mutations and 2679 without any ATM/ATR variations) from publicly available NGS databases.